I was comparing with skeletal events (presumably fractures) as an endpoint. I have no idea of what the rate of these is in late-stage populations is - conceivably of the same order as survival.
It's worth noting that the FDA has approved two drugs with pain reduction in prostate cancer as the primary endpoint - Mitoxantrone and Samarium. So that bolsters the notion that a combined pain/bone scan endpoint would be acceptable.
Market Data 
Markets 
AI
